Cemiplimab maintenance after chemo for advanced penile cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a drug called cemiplimab (an immunotherapy that helps your immune system fight cancer) can keep penile cancer from growing after you've finished your first round of chemotherapy. Participants will either get cemiplimab as a maintenance treatment or standard supportive care to see which helps better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man age 18 or older with a confirmed diagnosis of penile cancer that has spread or returned and can't be cured with surgery or radiation.
- You must have received at least 4 but no more than 6 cycles of first-line platinum-based chemotherapy (like cisplatin or carboplatin).
- Your cancer must not have gotten worse after that chemotherapy — it should be stable, smaller, or gone.
- You must be in reasonably good health, able to care for yourself (ECOG performance status of 0, 1, or 2).
- You can't have had certain prior treatments like certain immunotherapies (anti-PD-1, anti-PD-L1), and you cannot have an active autoimmune disease or an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests whether continuing treatment with cemiplimab (an immunotherapy drug) after initial chemotherapy can help keep vulvar cancer from growing, compared to standard supportive care. It is for people whose cancer is stable or improved after their first round of chemotherapy.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Hear when a new Penile Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.